Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Germany
/
Pharmaceuticals & Biotech
/
Evotec
EVT
Evotec
Inflation And Regulatory Challenges Will Erode Biopharma Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
26 Aug 25
Updated
26 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€6.00
1.1% undervalued
intrinsic discount
26 Aug
€5.94
1Y
-7.2%
7D
-3.3%
Loading
1Y
-7.2%
7D
-3.3%
Author's Valuation
€6.0
1.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€6.0
1.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-180m
880m
2014
2017
2020
2023
2025
2026
2028
Revenue €879.6m
Earnings €58.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.99%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.79%
Calculation
€58.16m
Earnings '28
x
21.73x
PE Ratio '28
=
€1.26b
Market Cap '28
€1.26b
Market Cap '28
/
178.21m
No. shares '28
=
€7.09
Share Price '28
€7.09
Share Price '28
Discounted to 2025 @ 5.77% p.a.
=
€5.99
Fair Value '25
